Aclaris Therapeutics (ACRS) Scheduled to Post Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Aclaris Therapeutics to post earnings of ($0.77) per share for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). The business had revenue of $5.04 million during the quarter, compared to the consensus estimate of $5.13 million. Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%. On average, analysts expect Aclaris Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ ACRS opened at $1.15 on Friday. The company has a market cap of $49.94 million, a P/E ratio of -0.29 and a beta of 0.77. The firm’s 50 day moving average price is $2.80. Aclaris Therapeutics has a one year low of $1.11 and a one year high of $18.98. The company has a quick ratio of 4.30, a current ratio of 4.33 and a debt-to-equity ratio of 0.16.

ACRS has been the subject of a number of analyst reports. Leerink Swann downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. Svb Leerink downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 8th. Finally, BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Aclaris Therapeutics currently has an average rating of “Hold” and a consensus target price of $19.69.

In other news, major shareholder James E. Flynn sold 454,261 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $4.59, for a total transaction of $2,085,057.99. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder James E. Flynn sold 699,475 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $2.69, for a total value of $1,881,587.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,107,983 shares of company stock worth $9,303,479. Insiders own 14.80% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: What is a Fiduciary?

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.